February 06, 2021
Although Serbia paid 4 million euros to COVAX last year, it has not yet received any shots and last month began its immunization campaign with vaccines from Pfizer, China's Sinopharm and Russia.
Recent manufacturing delays in Europe raise concerns about whether drugmakers will be able to fulfill the multiplying orders.
“There are so many deals being signed that I think it’s hard to see how the numbers could possibly add up for all the doses ordered to actually be produced in the foreseeable future,” said Amanda Glassman, a public health expert and executive vice-president of the Center for Global Development.